C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

(2016) Bo Ahrén et al.   DIABETOLOGIA

Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes

(2013) Tae Jung Oh et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients

(2012) Giuseppe Derosa et al.   Diabetes Technology & Therapeutics

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin

(2012) Anja Schweizer et al.   Diabetes Therapy

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

(2011) R. R. Henry et al.   DIABETES OBESITY & METABOLISM

DPP-4 inhibition and islet function

(2011) Bo Ahrén   Journal of Diabetes Investigation

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose

(2009) Gerlies Bock et al.   CLINICAL ENDOCRINOLOGY

Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes

(2008) David A. D'Alessio et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM